Astorg Portco-backed Solabia has finalized three strategic acquisitions, marking its first deals since the private equity firm's October 2025 investment. The Paris-based company, specializing in natural active ingredients for cosmetics, nutraceuticals, pharmaceuticals, food, and diagnostics, is expanding its biotechnology platform. Mibelle Biochemistry (Switzerland), Seqens' botanical actives and diagnostics unit (France), and Xebios Group (Germany) will bolster Solabia's portfolio. These moves accelerate its international growth strategy, broadening product capabilities and reinforcing its position in natural ingredients.

Solabia's portfolio companies, including Seqens, have signed definitive agreements for the complementary businesses. The acquisitions enhance Solabia's high-performance ingredient offerings across skin care, healthy ageing, hair care, cognitive health, and microbiological diagnostics for water, food, and clinical testing. The transactions underscore Solabia's alignment with Astorg's focus on specialized, innovation-driven platforms in healthcare and life sciences, aiming for disciplined long-term value creation.